Company intelligence / Profile preview

Achifar

Ownership: Private
Development stage: Other

Overview

Achira is a biotech startup founded in 2023 that leverages artificial intelligence, machine learning, quantum chemistry, and advanced molecular simulations to accelerate drug discovery. The company aims to shift the industry toward a computational-first approach where most early-stage research occurs in silico. As of mid-2025, Achira has raised $33 million from investors including Nvidia’s NVentures and Dimension VC. The first proprietary AI models are expected to be unveiled in 2025. No clinical results or pipeline assets have been disclosed yet.

Modalities: Small moleculeAI-powered drug discovery platform
Industry: Biotech

Partnerships

Nvidia NVentures participated as an investor

Beyond the preview

Go deeper on Achifar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achifar.

Explore the full profile